NS
Therapeutic Areas
LIR Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Transdermal GLP‑1 Patch | Obesity | Preclinical |
| GLP/GIP Transdermal Therapy | Obesity | Preclinical |
| Next‑Gen CPP Candidates | Obesity | Preclinical |
Leadership Team at LIR Life Sciences
EM
Ed Mills
CEO & Director
HN
Harry Nijjar
CFO and Corporate Secretary
MD
Mark Dybul, MD
Strategy Lead and Director
JC
Jonathan Campbell, PhD
Innovation Lead
PS
Peter Singer, MD
Global Health Lead
GS
Glenn Sammis, PhD
Chemistry Lead
PS
Patrick Smith, PhD
Drug Development Lead
KM
Kevin May
Director
CC
Constantine Carmichel
Director